HUP9602056A3 - Novel pharmaceutical composition containing phenofibrate - Google Patents

Novel pharmaceutical composition containing phenofibrate

Info

Publication number
HUP9602056A3
HUP9602056A3 HU9602056A HUP9602056A HUP9602056A3 HU P9602056 A3 HUP9602056 A3 HU P9602056A3 HU 9602056 A HU9602056 A HU 9602056A HU P9602056 A HUP9602056 A HU P9602056A HU P9602056 A3 HUP9602056 A3 HU P9602056A3
Authority
HU
Hungary
Prior art keywords
phenofibrate
pharmaceutical composition
composition containing
novel pharmaceutical
novel
Prior art date
Application number
HU9602056A
Other languages
English (en)
Original Assignee
Cl Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9481448&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP9602056(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cl Pharma filed Critical Cl Pharma
Publication of HU9602056D0 publication Critical patent/HU9602056D0/hu
Publication of HUP9602056A2 publication Critical patent/HUP9602056A2/hu
Publication of HUP9602056A3 publication Critical patent/HUP9602056A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
HU9602056A 1995-07-27 1996-07-26 Novel pharmaceutical composition containing phenofibrate HUP9602056A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9509142A FR2737121B1 (fr) 1995-07-27 1995-07-27 Nouvelles formulations galeniques du fenofibrate et leurs applications

Publications (3)

Publication Number Publication Date
HU9602056D0 HU9602056D0 (en) 1996-09-30
HUP9602056A2 HUP9602056A2 (en) 1997-06-30
HUP9602056A3 true HUP9602056A3 (en) 2000-09-28

Family

ID=9481448

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9602056A HUP9602056A3 (en) 1995-07-27 1996-07-26 Novel pharmaceutical composition containing phenofibrate

Country Status (12)

Country Link
US (1) US5827536A (hu)
EP (1) EP0757911B1 (hu)
JP (1) JPH09328427A (hu)
KR (1) KR970005285A (hu)
AT (1) ATE236628T1 (hu)
CA (1) CA2181422A1 (hu)
DE (2) DE69627253T2 (hu)
ES (1) ES2110377T1 (hu)
FR (1) FR2737121B1 (hu)
GR (1) GR980300014T1 (hu)
HU (1) HUP9602056A3 (hu)
ZA (1) ZA966067B (hu)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465016B2 (en) 1996-08-22 2002-10-15 Research Triangle Pharmaceuticals Cyclosporiine particles
KR100542816B1 (ko) 1996-08-22 2006-01-11 알티피 파마 코포레이션 수불용성 물질의 미립자를 포함하는 조성물 및 이것의 제조 방법
US6152991A (en) 1997-04-17 2000-11-28 Praxair Technology, Inc. Multilayer adsorbent beds for PSA gas separation
WO1999029300A1 (en) * 1997-12-10 1999-06-17 Rtp Pharma Inc. Self-emulsifying fenofibrate formulations
AU764001B2 (en) 1998-05-29 2003-08-07 Skyepharma Canada Inc. Thermoprotected microparticle compositions and process for terminal steam sterilization thereof
US6264960B1 (en) 1998-11-10 2001-07-24 Sander J. Robins Treatment of vascular events using lipid-modifying compositions
PL201578B1 (pl) 1998-11-20 2009-04-30 Skyepharma Canada Inc Stała terapeutyczna postać dawkowania nierozpuszczalnego lub słabo rozpuszczalnego w wodzie związku
US6814977B1 (en) 1998-12-18 2004-11-09 Abbott Laboratories Formulations comprising lipid-regulating agents
DE19858789A1 (de) 1998-12-18 2000-06-21 Bayer Ag Kombination von Cerivastatin und Fibraten
US6838091B2 (en) 1998-12-18 2005-01-04 Abbott Laboratories Formulations comprising lipid-regulating agents
US7014864B1 (en) 1998-12-18 2006-03-21 Abbott Laboratories Formulations comprising lipid-regulating agents
US6719999B2 (en) * 1999-03-31 2004-04-13 Abbott Laboratories Formulations comprising lipid-regulating agents
CA2270306C (en) * 1999-04-27 2000-09-26 Bernard Charles Sherman Pharmaceutical compositions comprising co-micronized fenofibrate
US6372251B2 (en) 1999-06-11 2002-04-16 Abbott Laboratories Formulations comprising lipid-regulating agents
US6982281B1 (en) 2000-11-17 2006-01-03 Lipocine Inc Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
FR2803203B1 (fr) * 1999-12-31 2002-05-10 Fournier Ind & Sante Nouvelles formulations galeniques du fenofibrate
US6682761B2 (en) 2000-04-20 2004-01-27 Rtp Pharma, Inc. Water-insoluble drug particle process
US6531158B1 (en) 2000-08-09 2003-03-11 Impax Laboratories, Inc. Drug delivery system for enhanced bioavailability of hydrophobic active ingredients
US8586094B2 (en) 2000-09-20 2013-11-19 Jagotec Ag Coated tablets
DE60129573T2 (de) * 2000-09-20 2008-04-17 Jagotec Ag Verfahren zur sprühtrocknung von zusammensetzungen enthaltend fenofibrat
FR2819720B1 (fr) * 2001-01-22 2004-03-12 Fournier Lab Sa Nouveaux comprimes de fenofibrate
PL202778B1 (pl) * 2001-02-22 2009-07-31 Skyepharma Canada Inc Postać dawkowana kombinacji statyny i fenofibratu, sposób jej wytwarzania i zastosowanie
KR20030076715A (ko) * 2001-03-01 2003-09-26 그레랑 파마수티컬 가부시키가이샤 페노피브라이트 함유 조성물
ITMI20011338A1 (it) * 2001-06-26 2002-12-26 Farmatron Ltd Composizioni farmaceutiche orali a rilascio immediato del principio attivo
DE60222803T2 (de) * 2001-12-21 2008-07-17 Supernus Pharmaceuticals, Inc. Orale kapselformulierung mit verbesserter physikalischer stabilität
US20030212138A1 (en) * 2002-01-14 2003-11-13 Pharmacia Corporation Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor
US20030220374A1 (en) * 2002-01-14 2003-11-27 Pharmacia Corporation Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
US20040005339A1 (en) * 2002-06-28 2004-01-08 Shojaei Amir H. Formulations of fenofibrate and/or fenofibrate derivatives with improved oral bioavailability
JP4783278B2 (ja) * 2003-02-03 2011-09-28 ノバルティス アーゲー 医薬製剤
CN1756756A (zh) 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
US7192944B2 (en) * 2003-03-07 2007-03-20 Schering Corp. Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
ATE406364T1 (de) 2003-03-07 2008-09-15 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
US8026281B2 (en) 2004-10-14 2011-09-27 Lupin Atlantis Holdings, S.A. Treating metabolic syndrome with fenofibrate
JP2008522972A (ja) * 2004-12-06 2008-07-03 レリアント ファーマスーティカルズ インコーポレイテッド 脂肪酸エステルを有する安定性フェノフィブラート組成物
KR101356335B1 (ko) * 2004-12-06 2014-02-06 릴라이언트 파마슈티컬스 인코퍼레이티드 지질 치료를 위한 오메가-3 지방산 및 이상지질혈증 제제
EP1861087A4 (en) * 2005-03-08 2010-02-10 Reliant Pharmaceuticals Inc TREATMENT WITH STATINE AND OMEGA-3-FATTY ACID AS A COMBINATION PRODUCT THEREOF
CA2601372A1 (en) * 2005-03-30 2006-10-12 Teva Pharmaceutical Industries Ltd. Improved formulations of fenofibrate containing menthol or peg/poloxamer
EA200701751A1 (ru) * 2005-03-30 2008-04-28 Тева Фармасьютикал Индастриес Лтд. Улучшенные составы фенофибрата
EP1707197A1 (en) 2005-03-30 2006-10-04 Teva Pharmaceutical Industries Ltd. Formulations containing fenofibrate and a surfactant mixture
US20070148233A1 (en) * 2005-12-28 2007-06-28 Lerner E I Pharmaceutical formulations of fenofibrate having improved bioavailability
US20070015833A1 (en) * 2005-07-18 2007-01-18 Moshe Flashner-Barak Formulations of fenofibrate containing menthol
ATE429902T1 (de) 2005-12-28 2009-05-15 Teva Pharma Pharmazeutische formulierungen mit fenofibrat mit verbesserter bioverfügbarkeit
KR20110027778A (ko) * 2008-07-03 2011-03-16 파나세아 바이오테크 리미티드 향상된 경구 생체 이용성을 갖는 페노피브레이트 제제
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
CA2924827C (en) 2013-09-18 2023-01-03 Georgetown University Treating neurodegenerative disease with fenofibrate and analogs thereof
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
JP2020503269A (ja) 2016-11-28 2020-01-30 リポカイン インコーポレーテッド 経口ウンデカン酸テストステロン療法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2494112B1 (hu) * 1980-11-19 1986-01-10 Laruelle Claude
FR2602423B1 (fr) * 1986-08-08 1989-05-05 Ethypharm Sa Procede de preparation d'un medicament a base de fenofibrate, medicament obtenu par ce procede
FR2617047B1 (fr) * 1987-06-23 1991-05-10 Sanofi Sa Composition de gelatine resistant au tannage, capsules a base de cette composition et leur application pharmaceutique, notamment au fenofibrate
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate

Also Published As

Publication number Publication date
DE69627253T2 (de) 2004-01-29
CA2181422A1 (fr) 1997-01-28
DE69627253D1 (de) 2003-05-15
GR980300014T1 (en) 1998-03-31
HU9602056D0 (en) 1996-09-30
FR2737121B1 (fr) 1997-10-03
ZA966067B (en) 1997-04-07
KR970005285A (ko) 1997-02-19
EP0757911A1 (fr) 1997-02-12
ES2110377T1 (es) 1998-02-16
JPH09328427A (ja) 1997-12-22
DE757911T1 (de) 1998-03-26
HUP9602056A2 (en) 1997-06-30
ATE236628T1 (de) 2003-04-15
FR2737121A1 (fr) 1997-01-31
US5827536A (en) 1998-10-27
EP0757911B1 (fr) 2003-04-09

Similar Documents

Publication Publication Date Title
HUP9602056A3 (en) Novel pharmaceutical composition containing phenofibrate
HUP9802999A3 (en) Pharmaceutical composition containing n-propargyl-1-aminoindan
HU9601698D0 (en) Pharmaceutical composition
HUP9601564A3 (en) Pharmaceutical composition containing irbesartan
IL122717A0 (en) Compounds and pharmaceutical compositions containing them
ZA967827B (en) Pharmaceutical compositions
EP0823255A4 (en) MEDICINAL PRODUCT CONTAINING SUCRAL FATE
GB9519667D0 (en) Pharmaceutical composition
ZA962214B (en) Pharmaceutical composition
ZA963590B (en) Pharmaceutical composition
EG24294A (en) Pharmaceutical compositions
GB9506382D0 (en) Pharmaceutical compositions
ZA96525B (en) Novel pharmaceutical compositions
GB9513972D0 (en) Pharmaceutical compositions
ZA961051B (en) Pharmaceutical composition
GB9525194D0 (en) Pharmaceutical composition
ZA964193B (en) Pharmaceutical composition
HUP9602822A2 (en) Pharmaceutical composition
ZA963591B (en) Pharmaceutical composition
GB2285923B (en) Pharmaceutical compositions containing N-acetal-cysteine
ZA95736B (en) Pharmaceutical composition
HUP9602732A2 (en) Pharmaceutical composition comprising lanperisone
GB9515207D0 (en) Pharmaceutical composition
GB9514807D0 (en) Pharmaceutical composition
GB9517063D0 (en) Pharmaceutical composition